Compare Cintas Corporation (CTAS) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Cintas Corporation trades at $191.14 (market cap $73.76B), while State Street SPDR S&P Biotech ETF trades at $155.18. The key difference: Cintas Corporation pays a 0.98% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Cintas Corporation nearer its low. Which is the better fit depends on your goals.
| CTAS | XBI | |
|---|---|---|
Market Cap | $73.76B | — |
Sector | Industrials | Broad Market / Factor |
52-Week High | $226.27 | $164.28 |
52-Week Low | $163.55 | $85.16 |
Enterprise Value | $76.49B | — |
Dividend Yield | 0.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cintas (CTAS) trades at $183.75, up 2.29% on the day, with a bullish technical outlook supported by moving averages and strong support at $182. The company shows robust fundamentals with revenue growing to $10.34B in 2025 and net income reaching $1.81B, though valuation ratios like P/E of 38.77 appear elevated. Recent news highlights upcoming Q4 earnings and continued recognition as a top employer.
The stock offers a compelling growth story with consistent earnings beats and a 43-year dividend growth track record, but faces risks from high valuation and economic sensitivity. Analyst consensus is mixed with a $212.50 price target, suggesting moderate upside potential if execution remains strong amid competitive pressures.
XBI trades at $155.34, down 2.32% on the day, but maintains a bullish technical outlook with strong momentum indicators. The biotech ETF has gained significant attention after a 17% monthly surge, driven by sector rotation and M&A activity. Analyst coverage remains limited with a single hold rating, though recent news highlights biotech's strong performance amid market volatility.
The ETF offers exposure to biotech's resurgence with AI drug discovery and deal momentum as catalysts. However, high volatility and concentrated sector risk require careful position sizing. Current technical strength suggests potential for continued upside if sector momentum persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
